Sponsor:
Ottawa Hospital Research Institute
Code:
NCT05969275
Conditions
Septic Shock
Sepsis
Pathologic Processes
Shock
Systemic Inflammatory Response Syndrome
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Allogeneic umbilical cord-derived human mesenchymal stromal cells
Placebo
Brief summary:
Conditions
Septic Shock
Sepsis
Pathologic Processes
Shock
Systemic Inflammatory Response Syndrome
Study ID
NCT05969275
Start date
Feb 14, 2024
Status verified date
Dec, 2024
Completion date
Mar 31, 2027
Anticipated
Primary completion date
Sep 30, 2026
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
296 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Treatment
Arms
experimental: Umbilical Cord Mesenchymal Stromal Cells (UC-MSCs)
placebo comparator: Placebo
Interventions
Allogeneic umbilical cord-derived human mesenchymal stromal cells
Placebo
Primary outcome measure
Central contacts
Locations
The Ottawa Hospital (General Campus)
Recruiting
Ottawa, Ontario, Canada, K1H 8L6
Contacts
Irene Watpool, RN
UCCISS@ohri.caPrincipal Investigator:
Lauralyn McIntyre, MD
The Ottawa Hospital (Civic Campus)
Recruiting
Ottawa, Ontario, Canada, K1Y 4E9
Contacts
Rebecca Porteous, RN
UCCISS@ohri.caPrincipal Investigator:
Lauralyn McIntyre, MD
Sponsor
Ottawa Hospital Research Institute
Last update posted
Dec 5, 2024
Last verified
Dec, 2024
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Ottawa Hospital Research Institute on 2024-12-05.